Several posts emphasize the revolutionary aspect of Australia's tumor-agnostic approvals, with phrases like 'first totally agnostic approvals' and 'landmark reimbursement shift,' reflecting high interest and recognition. The tone is enthusiastic and informative, highlighting both scientific and policy advances, which demonstrates deep engagement and underscores the global impact of this healthcare reform.
AgreementStrong agreement
Posts strongly support the significance of Australia's landmark immunotherapy reimbursement, emphasizing its novelty and benefits.
InterestHigh interest
The discussion highlights the groundbreaking nature of the policy and its potential benefits for rare cancers, which naturally piques interest.
EngagementHigh engagement
Posts include details about study findings, expected benefits, and international recognition, indicating deep engagement with the topic.
ImpactHigh impact
The coverage portrays this as a major healthcare milestone with global significance, showing high potential impact.
Top posts
Most liked on X and Bluesky
VM
Vivek Subbiah, MD
@VivekSubbiah · X
⭐️?Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement | Journal of Clinical Oncology @JCO_ASCO @ASCO @Dr_R_Kurzrock @OncoAlert https://t.co/X62lX0SzH8
Oct 10, 2026 · 46 likes · 21 shares · 41,377 followersView post →
VM
Vivek Subbiah, MD
@VivekSubbiah · X
?⭐️Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement | Journal of Clinical Oncology @JCO_ASCO @ASCO @Dr_R_Kurzrock @OncoAlert https://t.co/X62lX0SzH8
Oct 2, 2026 · 35 likes · 5 shares · 41,377 followersView post →
RM
Razelle Kurzrock, MD
@Dr_R_Kurzrock · X
The first totally agnostic approvals. Because we don’t know everything about IO biomarkers. And because our DART study showed that a subset of patients with refractory rare cancers achieve long-term disease-free remissions (aka cures) https://t.co/8a8J0JGVnK https://t.co/YRNuH0UT8X
Oct 10, 2026 · 24 likes · 5 shares · 8,917 followersView post →
NP
Nieves Martinez Lago MD PhD
@DraMartinezLago · X
? Tumor-agnostic immunotherapy | Australia ??
? Nivo + ipi: pan-tumor PBS access
➕ Pembrolizumab follows
? ~5,000 pts/year expected to benefit
? Major opportunity for rare cancers
? A landmark reimbursement shift.
? https://t.co/FEFc4OIkEu
@OncoAlert https://t.co/EhRBfCmg4y
Oct 2, 2026 · 19 likes · 6 shares · 3,639 followersView post →
AF
A Nasser Nourallah. MD.FASCO
@a_nourallah · X
Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement | Journal of Clinical Oncology https://t.co/WwLWyOskRd
Tucatinib receives expanded FDA approval for first-line treatment of HER2-positive metastatic breast cancer based on HER2-Climb05 results. Pirtobrutinib is approved for initial CLL/SLL treatment without 17p deletion…
The first totally agnostic approvals. Because we don’t know everything about IO biomarkers. And because our DART study showed that a subset of patients with refractory rare cancers achieve long-term disease-free remissions (aka cures) https://t.co/8a8J0JGVnK https://t.co/YRNuH0UT8X
Oct 10, 2026 · 24 likes · 5 shares · 8,917 followersView post →
VM
Vivek Subbiah, MD
@VivekSubbiah · X
⭐️?Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement | Journal of Clinical Oncology @JCO_ASCO @ASCO @Dr_R_Kurzrock @OncoAlert https://t.co/X62lX0SzH8
Oct 10, 2026 · 46 likes · 21 shares · 41,377 followersView post →
AP
ARC Portal
@arcportal.org.au · Bluesky
Australia’s landmark approach to immunotherapy access is gaining international recognition. ??
ascopubs.org/doi/10.1200/...
ARC Portal is proud to see this PBS reform recognised as a global milestone, particularly for people with rare and ultra-rare cancers.
Australia’s landmark approach to immunotherapy access is gaining international recognition. ??
https://t.co/v3hM0wH8wY
ARC Portal is proud to see this PBS reform recognised as a global milestone, particularly for people with rare and ultra-rare cancers.
Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement | Journal of Clinical Oncology https://t.co/WwLWyOskRd
... 10.1200/JCO-26-01340 Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm. Oct 8. 13 min ...
MD Ph.D. eMBA | Global Drug Development | Bayer Science Fellow · Husband, Father of 4, Ironman. Close to my heart: Data Science, Clinical Research, ...
Vineet Kwatra - Medical Oncologist | Director at Cancer Research ...
LinkedIn
Medical Oncologist | Director at Cancer Research SA (CRSA) · Experienced Medical Oncologist with a demonstrated history of working in the hospital & health ...
Noémie Simon-Tillaux - MD, PhD en Santé Publique | LinkedIn
LinkedIn
MD, PhD en Santé Publique · I am trained physician and currently working as methodologist and biostatistician at the Biostatistics and Epidemiology Office ...
10.1200/JCO-26-01340. Contributors: Vivek Subbiah; Razelle Kurzrock. Show more detail. Source: check_circle. Crossref. The Multifaceted Roles of STAT6 ...
VM
RM
NP
AF
G
AP
AP